- EGFR Signaling Pathway
- TGF-beta Signaling
- Canonical Wnt Signaling
- non-Canonical Wnt Signaling
- Notch Signaling
- p53 Pathway
- NF-kB Pathway
- Cytokine Signaling
|Catalog||Size (Price)||Quantity||In Stock||Operation|
B and T lymphocyte associated Protein Datasheet
BTLA Protein Price Inquiry ( Available Sizes )
BTLA Protein Product Information
A DNA sequence encoding the mouse BTLA(Met1-Gly176) was expressed, fused with the Fc region of human IgG1 at the C-terminus.
|Expression Host:||Human Cells|
BTLA Protein QC Testing
|Purity:||> 90 % as determined by SDS-PAGE||SDS-PAGE:
|Immobilized mouse BTLA-Fc at 10 μg/ml (100 μl/well) can bind biotinylated mouse HVEM-Fch (Cat:10567-M03S), The EC50 of biotinylated mouse HVEM-Fch (Cat:10567-M03S) is 15.7-36.7 ng/ml.|
|Endotoxin:||< 1.0 EU per μg of the protein as determined by the LAL method|
|Stability:||Samples are stable for up to twelve months from date of receipt at -70℃|
|Predicted N terminal:||Glu 30|
The recombinant mouse BTLA /Fc is a disulfide-linked homodimer. The reduced monomer comprises 388 amino acids and has a predicted molecular mass of 437 kDa. The apparent molecular mass of the protein is approximately 57-62 kDa in SDS-PAGE under reducing conditions due to glycosylation.
|Formulation:||Lyophilized from sterile PBS, pH7.4.
BTLA Protein Usage Guide
|Storage:||Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.|
|Reconstitution:||A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.|
BTLA Protein Related Products & Topics
BTLA Protein Description
BTLA is a member of the immunoglobulin superfamily. It contains a single immunoglobulin (Ig) domain and is a receptor that relays inhibitory signals to suppress the immune response. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. BTLA is one of a growing number of inhibitory molecules that down-modulates immune responses. As such, reagents that regulate the binding of BTLA to its ligand or alter BTLA signaling have significant therapeutic promise. BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1). Polymorphisms in BTLA gene have been associated with an increased risk of rheumatoid arthritis.
- Fourcade J. et al., 2012, Cancer Res. 72 (4): 887-96.
- Kojima R. et al., 2011, J Mol Biol. 413 (4): 762-72.
- Oki M. et al., 2011, Clin Dev Immunol. 305656.